Arpeggio Biosciences

Executive Summary

Arpeggio Biosciences is a privately held biotechnology company based in Boulder, Colorado, founded in 2016. The company leverages artificial intelligence and transcriptomic drug screening to develop novel small molecule therapies that target biological networks, with a particular focus on traditionally 'undruggable' transcription factors. Rather than targeting single molecular targets, Arpeggio's platform aims to modulate entire disease-relevant networks, offering a differentiated approach for treating serious diseases. Its initial therapeutic focus is on lung cancer, with potential expansion into other indications. The company operates in the AI/Machine Learning category and is at an early stage of development, with no disclosed funding, valuation, or revenue. Its private status and lack of public pipeline data limit visibility, but its innovative approach to tackling difficult targets positions it as a potential player in precision oncology and beyond.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement50% success
• H1 2027Preclinical Proof-of-Concept Data for Lead Lung Cancer Program40% success
• 2027Partnership with Major Pharma or Academic Center30% success